Development and characterization of AD-214, an anti-CXCR4 i-body-Fc fusion for the treatment of idiopathic pulmonary fibrosis

Development and characterization of AD-214, an anti-CXCR4 i-body-Fc fusion for the treatment of idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by scarring and tissue remodeling. Current treatments have limited efficacy and significant side effects. To address these limitations, we developed AD-214, an anti-CXCR4-Fc-fusion protein composed of an anti-CX...

Full description

Saved in:
Bibliographic Details
Main Authors: Jason P. Lynch, Louise Organ, Khamis Tomusange, Lukasz Kowalczyk, Dallas J. Hartman, Angus Tester, Chris Hosking, Michael Foley
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:mAbs
Subjects:
AD-214
CXCR4
Fc-fusion
fibrotic disease
i-body
idiopathic pulmonary fibrosis
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2025.2505090
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items